The clinical-stage biotech company will leverage AGC’s BravoAAV suspension platform for two novel candidates to address progressive and irreversible vision loss.
Expansion at the facility will roll out in phases and position the South Korea–based biosimilars manufacturer to build an integrated U.S. manufacturing supply chain.
The Australia-headquartered biopharma company will expand its footprint in the United States. Since 2018, it has invested over $3 billion in U.S. operations.
The deal grants Andelyn’s gene therapy clients with access to Solid’s capsid in combination with the CDMO’s suspension and adherent platform manufacturing process.
The cross-disciplinary panel is meant to provide independent recommendations and governance guidance to Fujifilm’s life sciences and healthcare subsidiaries.
The new site adds research capacity and reportedly strengthens the company’s U.S. footprint beyond its existing facility and manufacturing operations in New Jersey.
The project includes digital transformation initiatives and process-innovation technologies to more than double production capacity at the company’s Ansan site.
The new location in Research Triangle Park strengthens AES’s support for the expanding life sciences and manufacturing industries in the Southeastern United States.
The partnership aims to strengthen financial flexibility and accelerate international growth for the bioconjugate-focused contract research, development, and manufacturing organization...
The company’s proprietary manufacturing enhancers reportedly boost adeno-associated virus production efficiency, while maintaining product integrity across scales.
The newly formed company from the businesses of Mallinckrodt and Endo, which merged in July 2025, will focus on branded therapeutics for rare and underserved conditions.
The collaboration combines mRNA sequence optimization with end-to-end GMP manufacturing to support streamlined development and clinical-scale production.
The completed deal expands Sandoz’s biosimilar manufacturing footprint while enabling Evotec to transition toward a more asset-light, technology-driven business model.
The $22.2 million agreement aims to advance domestic production of monoclonal antibodies to protect against filoviruses such as Ebola and Sudan viruses.
The collaboration aims to strengthen the U.S. advanced pharmaceutical manufacturing workforce through a new industry-led education and training network.